A
ASM AtlasAntiseizure medication reference

Choose with context.

Find medications by clinical use, age, formulation or mechanism. Compare up to four.

Draft clinical reference · independent human review pending

Syndrome-specific treatment guideIGE · absence · JME · GTCA · Dravet · LGS · spasms · SeLECTS · CDD

Clinical selection guidance complements the product library. U.S. approvals, UK NICE recommendations and trial evidence are identified separately. Drug lists below are options to review, not ranked prescriptions.

Age, route and seizure filters must match the same product record. Unmapped ages/formulations are excluded when specified. Results indicate label or guideline coverage, not patient suitability. Caution filters highlight issues to review.

Try “1,4-benzodiazepines”, “GABA-A”, “SV2A”, or “sodium channel”. Mechanism groups include proposed actions; see each profile for evidence and qualifications.

Practical prescribing: formulations, concentrations & withdrawal
Formulation matters
Check the exact product, concentration, release type and route. A liquid, sprinkle, dissolving tablet and buccal rescue film can have different instructions and indications. Crush or use a feeding tube only when that product’s instructions support it. See the added administration notes in individual profiles.
Generic substitution
FDA-approved bioequivalent generics are supported by AES. Match the release formulation: immediate-release is not a substitute for delayed- or extended-release. Explain changes in tablet appearance and dosing to support adherence. AES position statement ↗
When to check a level
Consider concentrations for unexplained seizures, adverse effects, suspected missed doses, pregnancy, renal changes or important interactions. Use the individual effective baseline where available; interpret the local assay and timing. Routine levels are unnecessary for many stable patients.
Free versus total
Valproate and phenytoin total levels can mislead when protein binding changes. Consider a measured free level when clinically indicated. Clobazam and its metabolite are reported in ng/mL; several other ASMs use mcg/mL. Profiles link verified laboratory intervals.
Bone health
Long-term treatment with certain ASMs, including carbamazepine, phenytoin, primidone and valproate, can adversely affect bone health. Assess individual risk and consider vitamin D/calcium supplementation when appropriate.
Planned withdrawal
Seizure freedom does not automatically mean medication can stop. Agree a syndrome-specific relapse-risk assessment and taper with the clinician. For elective withdrawal, NICE usually recommends at least 3 months, longer for benzodiazepines/barbiturates, and one drug at a time. Urgent adverse reactions require a different plan; label minimum tapers are not universal withdrawal schedules.

NICE NG217: monitoring, bone health and withdrawal (UK) ↗

Sources, editorial status & corrections

This draft uses U.S. product labeling, selected trials and clearly identified guideline sources. Content has been assembled and checked with AI assistance. No independent human clinical review or endorsement is claimed.

Author / reviewer credentials
Public author and reviewer identities have not yet been supplied. Independent clinical review is pending.
Conflicts of interest
A disclosure statement has not yet been supplied.
Correction contact
A public contact address has not yet been supplied. Download a correction report below and send it to the site owner through your existing contact channel.

Workbook-informed revision — September 14, 2026

How the supplied workbook was used

Medication cells and relevant pasted medication/treatment tables were used to identify topics for verification. Diagnostic, EEG and genetics tables were outside the requested scope. Original screenshots are not reproduced.

  • Corrected older ganaxolone dosing, clobazam concentration units, food/crushing instructions and age/indication generalizations.
  • Rejected a stiripentol GAT-1 attribution and an apparent Dravet treatment list under SeLECTS.
  • Did not import obsolete pregnancy letter categories, blanket prenatal vitamin K advice or an unsupported universal “effective for” matrix.

AI-assisted clinical critique informed these revisions. Independent human epilepsy-specialist review remains pending.

Earlier changes — September 14, 2026

Product source audit — 31 profiles

Source retrieval and a partial audit do not establish complete verification. Not all brands, dose regimens, laboratory intervals or trial outcomes have been re-extracted. Each row links the exact product label used and identifies remaining work.

MedicationLabel revision / sourceReview status & gaps

Prepare a correction report

No patient details, please. This form downloads a report; it does not send a message.